Effect of platinum-based chemoradiotherapy on cellular proliferation in bone marrow and spleen, estimated by 18F-FLT PET/CT in patients with locally advanced non-small cell lung cancer

Journal of Nuclear Medicine

Volumn 55, Issue 7, 2014, Pages 1075-1080

  Leimgruber, Antoine ^a,b   Möller, Andreas ^c   Everitt, Sarah J ^a,d,e   Chabrot, Marine ^a   Ball, David L ^a,d   Solomon, Ben ^a,d   MacManus, Michael ^a,d   Hicks, Rodney J ^a,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Bone marrow; Chemotoxicity; Hematopoiesis; Spleen

Indexed keywords

3' FLUOROTHYMIDINE F 18; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; GLUCOSE; PLATINUM;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW CELL; CELL PROLIFERATION; CHEMORADIOTHERAPY; CLINICAL EVALUATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG CYTOTOXICITY; FEMALE; GLUCOSE METABOLISM; HUMAN; LIVER; LIVER CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIOISOTOPE DISTRIBUTION; SMALL INTESTINE; SPLEEN; SPLEEN CELL; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; ADVERSE EFFECTS; ANTIBODY SPECIFICITY; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; CHEMISTRY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DIAGNOSTIC USE; DRUG EFFECTS; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; NEUTROPHIL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIATION RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW CELLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL COUNT; CELL PROLIFERATION; CHEMORADIOTHERAPY; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPHILS; ORGAN SPECIFICITY; PLATINUM; POSITRON-EMISSION TOMOGRAPHY; SPLEEN; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84904135727     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.136127     Document Type: Article

References (34)

1. Holland JP, Cumming P, Vasdev N. PET of signal transduction pathways in cancer. J Nucl Med. 2012;53:1333-1336.
2. 18F-FDG PET in assessment of response in non-small cell lung cancer. J Nucl Med. 2009;50:31S-42S.
3. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340-3346. (Pubitemid 28193885)
4. 18F-FDG PET/CT bone/bone marrow findings in Hodgkin's lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095-1105.
5. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003;44:224-239.
6. Bading JR, Shields AF. Imaging of cell proliferation: status and prospects. J Nucl Med. 2008;49:64S-80S. (Pubitemid 351948037)
7. 18F- fluorothymidine uptake in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2012;48:3499-3513.
8. Luo J, Leaw SJ, Xu Y, Zheng D. Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer. Med Oncol. 2011;28:1418-1424.
9. 18F]fluorothymidine PET quantification of bone marrow response to radiation dose. Int J Radiat Oncol Biol Phys. 2011;81:888-893.
10. Agool A, Slart RHJA, Thorp KK, et al. Effect of radiotherapy and chemotherapy on bone marrow activity. Nucl Med Commun. 2011;32:17-22.
11. 18F-FLT PET in hematologic disorders: a novel technique to analyze the bone marrow compartment. J Nucl Med. 2006;47:1592-1598.
12. 18F]FLT PET imaging. Leuk Res. 2011;35:310-316.
13. Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013;39:806-818.
14. Cortez-Retamozo V, Etzrodt M, Newton A, et al. Angiotensin II drives the production of tumor-promoting macrophages. Immunity. 2013;38:296-308.
15. López-Guillermo A, Cervantes F, Bruguera M, Pereira A, Feliu E, Rozman C. Liver dysfunction following splenectomy in idiopathic myelofibrosis: a study of 10 patients. Acta Haematol. 1991;85:184-188.
16. 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:1098-1104.
17. OSI3926g Study Team, Binns DS, Pirzkall A, et al. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:642-650.
18. Kralovánszky J, Prajda N, Kerpel-Fronius S, Gál F, Kiss F. Comparison of intestinal toxic effects of platinum complexes: cisplatin (CDDP), carboplatin (CBDCA), and iproplatin (CHIP). Cancer Chemother Pharmacol. 1988;21:40-44. (Pubitemid 18050479)
19. 18F]fluorothymidine uptake in the bone marrow before and early after initiation of chemoradiation therapy in head and neck cancer. Nucl Med Biol. 2010;37:433-438.
20. Hayman JA, Callahan J, Herschtal A, et al. Distribution of proliferating bone marrow in adult cancer patients determined using FLT-PET imaging. Int J Radiat Oncol Biol Phys. 2011;79:847-852.
21. 18]FLT and positron emission tomography. Nat Med. 1998;4:1334-1336.
22. 18F]fluorothymidine- positron emission tomography imaging: evaluation of analytical methods. Cancer Res. 2005;65:10104- 10112.
23. Awasthi V, Holter J, Thorp K, Anderson S, Epstein R. F-18- fluorothymidine-PET evaluation of bone marrow transplant in a rat model. Nucl Med Commun. 2010;31:152-158.
24. Gomez DR, Tucker SL, Martel MK, et al. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;84:1010-1016.
25. Nijkamp J, Rossi M, Lebesque J, et al. Relating acute esophagitis to radiotherapy dose using FDG-PET in concurrent chemo-radiotherapy for locally advanced non-small cell lung cancer. Radiother Oncol. 2013;106:118-123.
26. Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85:444-450.
27. Spivak JL, Barosi G, Tognoni G, et al. Chronic myeloproliferative disorders. Hematology (Am Soc Hematol Educ Program). 20032003:200-224.
28. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29:573-582.
29. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science. 2009;325:612-616.
30. Cortez-Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA. 2012;109:2491-2496.
31. Wang Y, Meng Q, Qiao H, Jiang H, Sun X. Role of the spleen in cyclophosphamide-induced hematosuppression and extramedullary hematopoiesis in mice. Arch Med Res. 2009;40:249-255.
32. Kondo M, Oshita F, Kato Y, Yamada K, Nomura I, Noda K. Early monocytopenia after chemotherapy as a risk factor for neutropenia. Am J Clin Oncol. 1999;22:103-105. (Pubitemid 30261603)
33. Blay JY, Chauvin F, Le Cesne A, et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol. 1996;14:636-643. (Pubitemid 26051031)
34. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol. 2007;25:571-578. (Pubitemid 350002965)